Curis (CRIS) risk factors

57 risks, 8 new, 8 dropped, 17 reworded since the prior year. Curis faces intense competition for its lead drug emavusertib across multiple oncology indications. The company added new risks regarding FDA funding and potential 100% tariffs on imported branded drugs. Curis received a Nasdaq delisting notice for failing minimum bid price requirements.

57 risks. Curis faces going concern doubts and net losses, with $20.0 million in cash as of December 31, 2024. The business relies heavily on the clinical success and commercialization of emavusertib. Royalty revenue depends on Genentech and Roche sales of Erivedge.